Akèy › Limfòm Burkitt › Wisconsin › Milwaukee
Etid klinik pou Limfòm Burkitt nan Milwaukee, WI
16 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan ak bò kote Milwaukee (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 2
- Children's Hospital of Wisconsin, Milwaukee
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Ap rekriteFaz 3
- Medical College of Wisconsin, Milwaukee
Blinatumomab Consolidation in Real World
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Medical College of Wisconsin, Milwaukee
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
- Children's Hospital of Wisconsin, Milwaukee
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Ap rekriteFaz 2
- Medical College of Wisconsin, Milwaukee
- Drexel Town Square Health Center, Oak Creek · 11 mi lwen
- Froedtert and MCW Moorland Reserve Health Center, New Berlin · 11 mi lwen
- ak 1 plis
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Ap rekriteFaz 2
- Children's Hospital of Wisconsin, Milwaukee
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- Medical College of Wisconsin, Milwaukee
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 1
- Medical College of Wisconsin, Milwaukee
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 2
- Children's Hospital of Wisconsin, Milwaukee
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Ap rekriteFaz 3
- Children's Hospital of Wisconsin, Milwaukee
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Ap rekriteFaz 1/2
- Research Site, Milwaukee
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Ap rekriteFaz 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Ap rekrite
- Children's Wisconsin, Milwaukee
Study of SGR-1505 in Mature B-Cell Neoplasms
Ap rekriteFaz 1
- Medical College of Wisconsin, Milwaukee
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Ap rekriteEtid obsèvasyon
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Ap rekriteFaz 2
- Children's Hospital of Wisconsin, Milwaukee
Etid Limfòm Burkitt nan lòt vil
- Houston, TX21 etid
- Philadelphia, PA16 etid
- New York City, NY14 etid
- Chicago, IL14 etid
- Cincinnati, OH12 etid
- Atlanta, GA12 etid
- Seattle, WA11 etid
- Durham, NC10 etid
- Boston, MA10 etid
- Los Angeles, CA10 etid
- Aurora, CO10 etid
- Kansas City, MO10 etid
Lòt etid nan Milwaukee
- Kansè nan tete23 etid
- Kansè Poumon ki pa ti selil22 etid
- Kansè (tout kalite)22 etid
- Kansè poumon21 etid
- Myelom Miltip21 etid
- Kansè pwostat20 etid
- Limfòm folikilè19 etid
- Kansè pankreyas18 etid
- Limfòm Non-Hodgkin18 etid
- Kansè ovè17 etid
- Leksemi mieloïd egi17 etid
- Ensifizyans kadyak16 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.